Patients, researchers, and clinicians are recognizing the potential of spinal biologics to treat challenging painful conditions. While the roles of both nonoperative and surgical treatment are relatively well-defined in the algorithm of spine care, the indications, risks, and concerns regarding biologics for a variety of spinal conditions have not been agreed upon. Because of the differences in regulatory pathways for many of these products, the availability of data is variable, making administrative decision-making difficult.

You’re invited to join experts from academia and industry to discuss the pertinent technologies and relevant issues in biologics use for spinal conditions at this November 13 meeting in Nashville, TN.

Why Attend?

✔ Learn what's hype, and what's backed by evidence.
✔ Compare today's leading biologic technologies.
✔ Understand FDA pathways and regulatory considerations.
✔ Explore grafts, BMPs, bioactive materials, and tissue products.
✔ Bust common myths about spine biologics.
✔ Discover what's next in disc, soft tissue, and nerve regeneration.